论文部分内容阅读
目的:分析糖皮质激素在肿瘤内科临床应用的疗效和安全性。方法:回顾性分析70例应用糖皮质激素治疗的肿瘤患者的临床资料,根据不同使用剂量将其分为A组(18例)、B组(22例)和C组(30例),比较三组临床疗效及不良反应情况。结果:三组患者在恶心呕吐、过敏反应、脊髓压迫等方面比较差异并不显著(P>0.05),在局部水肿、颅内高压等方面比较差异具有显著性(P<0.05);其中C组患者各种不良反应发生率明显高于A组和B组,比较差异具有显著性(P<0.05)。结论:对于肿瘤患者而言,中、低剂量糖皮质激素能够起到较好的临床疗效,且不良反应较少。
Objective: To analyze the clinical efficacy and safety of glucocorticoid in oncology. Methods: The clinical data of 70 patients with cancer treated with glucocorticoids were retrospectively analyzed. The patients were divided into group A (n = 18), group B (n = 22) and group C (n = 30) Group clinical efficacy and adverse reactions. Results: There was no significant difference in nausea, vomiting, anaphylaxis and spinal cord compression between the three groups (P> 0.05), and there was significant difference in local edema and intracranial hypertension (P <0.05) The incidence of various adverse reactions in patients was significantly higher than that in A and B groups, with significant difference (P <0.05). Conclusion: For patients with cancer, moderate and low doses of glucocorticoids can play a good clinical efficacy, and fewer adverse reactions.